• Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
META-ANALYSIS
Year : 2017  |  Volume : 3  |  Issue : 4  |  Page : 146-152

Efficacy and safety of paclitaxel-based therapy and nonpaclitaxel-based therapy in advanced gastric cancer


Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Correspondence Address:
Xiaolong Qi
Department of General Surgery, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou 510515, Guangdong
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ctm.ctm_1_17

Rights and Permissions

Aim: To compare the efficacy and safety of paclitaxel-based therapy versus nonpaclitaxel-based therapy in patients with advanced gastric cancer (AGC). Methods: An adequate literature search in MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, American Society of Clinical Oncology and European Society of Medical Oncology was conducted. Phase II/III randomized controlled trials that detected the efficacy and safety of paclitaxel-based therapy and nonpaclitaxel-based therapy in AGC patients were enrolled. Overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events were included in the endpoints. Results: A total of 632 patients in seven studies of were reviewed. There was a significant difference in ORR between paclitaxel and placebo therapy (odd ratio [OR] =2.68, 95% confidence interval [CI] = 1.05–6.86, P = 0.04), but not between paclitaxel and irinotecan, cisplatin or docetaxel. As no first-line treatment, paclitaxel-based therapy significantly increased ORR (OR = 1.55, 95% CI = 1.02–2.34, P = 0.04, I2 = 0%). No significant differences were found in PFS and OS between paclitaxel- and nonpaclitaxel-based therapies. In addition, paclitaxel-based therapy generally decreased the risk of vomiting and stomatitis while increased the risks of leukopenia and sensory neuropathy. Conclusion: Paclitaxel-based therapy improved ORR in AGC patients as no first-line therapy, but no significant difference was observed for PFS and OS.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed485    
    Printed14    
    Emailed0    
    PDF Downloaded64    
    Comments [Add]    

Recommend this journal